Skvrce Nikica Mirosević, Bozina Nada, Sarinić Viola Macolić, Tomić Sinisa
Agencija za lijekove i medicinske proizvode, Zagreb.
Lijec Vjesn. 2010 Sep-Oct;132(9-10):277-82.
Hydroxymethylglutaryl-CoA reductase inhibitors (statins) are drugs used in the treatment of chronic diseases and frequently in concomitant therapy with many other drugs. Therefore, the risk of adverse drug reactions (ADRs), especially those caused by interactions is high. Aim of the study was to describe and analyze ADRs caused by statins reported to Croatian Agency from March 2005 to December 2008, and to emphasize reasons of their occurrence. 136 of statin ADRs were reported. 12 % of all reported statins' ADRs were caused by interactions, which is higher than percent (5.6%) of interactions caused by all other drugs in 2005 and 2006. Proportion of serious ADRs related to administered dose and thus preventable was higher than proportion of all ADRs caused by statins (p = 0.003). Most serious ADRs could have been prevented with better understanding of interactions and by use of pharmacogenomics in identifying patients that are because of genetic predisposition more sensitive to standard doses.
羟甲基戊二酰辅酶A还原酶抑制剂（他汀类药物）是用于治疗慢性疾病的药物，并且经常与许多其他药物联合使用。因此，药物不良反应（ADR）的风险，尤其是由相互作用引起的风险很高。本研究的目的是描述和分析2005年3月至2008年12月向克罗地亚机构报告的他汀类药物引起的ADR，并强调其发生原因。报告了136例他汀类药物的ADR。所有报告的他汀类药物ADR中有12%是由相互作用引起的，这高于2005年和2006年所有其他药物引起的相互作用的百分比（5.6%）。与给药剂量相关且可预防的严重ADR的比例高于他汀类药物引起的所有ADR的比例（p = 0.003）。通过更好地理解相互作用以及使用药物基因组学来识别由于遗传易感性对标准剂量更敏感的患者，大多数严重ADR本可以预防。
